The authors wish to make the following corrections to this paper [1]:
- Add a citation in the Introduction section
In the original publication, the publication from Lucas Basler et al. [2] was not cited. The citation has now been inserted in the Introduction as reference [9]:
In order to predict the response to immunotherapy several outcome predictive biomarkers based on the histopathology of the primary tumor (i.e., tumor thickness, ulceration, mitotic rate) [8], standard blood samples (i.e., lactate dehydrogenase LDH, calcium-binding protein B S100B) [9] or clinical aspects (i.e., sentinel lymph node involvement, anatomical site of primary tumor, gender or age) [10] have been already discussed in the literature.”
- 2.
- Ethical approval information needs to be updated:
The official and correct reference of the stated ethical approval is KEK-ZH-Nr: 2014-0193.
The correct statement is as below:
Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Cantonal Ethics Committee of the Canton Zurich in Switzerland (protocol code KEK-ZH-Nr: 2014-0193) on 15 March 2017.
2.1. Patient Cohort
(…). All included patients consented the use of their clinical data for research purposes. This study was approved by the local ethics committee (protocol code KEK-ZH-Nr: 2014-0193) and conducted in compliance with Good Clinical Practice GCP-rules and the Declaration of Helsinki.
- 3.
- Missing Funding
In the original publication, the funder Cancer Research Center, Comprehensive Center Zurich, University Hospital Zurich (CRC_13) was not included.
The correct statement is as:
Funding: This research was funded by the Iten-Kohaut-Foundation (IA USZF27071) and the Cancer Research Center, Comprehensive Center Zurich, University Hospital Zurich (CRC_13).
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.
References
- Kudura, K.; Dimitriou, F.; Basler, L.; Förster, R.; Mihic-Probst, D.; Kutzker, T.; Dummer, R.; Mangana, J.; Burger, I.A.; Kreissl, M.C. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830. [Google Scholar] [CrossRef] [Scilit]
- Basler, L.; Gabryś, H.S.; Hogan, S.A.; Pavic, M.; Bogowicz, M.; Vuong, D.; Tanadini-Lang, S.; Förster, R.; Kudura, K.; Huellner, M.W.; et al. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma treated with Immune Checkpoint Inhibition. Clin. Cancer Res. 2020, 26, 4414–4425. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).